Why is PCSK9 an ideal target to improve LDL cholesterol goal attainment?

PCSK9 (proprotein convertase subtilisin/kexin type 9) is a key player in the regulation of circulating LDL cholesterol levels. Over 15 years ago, researchers showed that individuals with mutations in the PCSK9 gene associated with gain of PCSK9 activity were at increased risk of premature cardiovascular disease due to very high cholesterol levels. This finding provided the impetus for the search for novel agents targeting PCSK9: the PCSK9 revolution.

The latest complementary slide resource from PCSK9 Forum discusses the evidence for PCSK9 as a novel therapeutic target in very high risk patients, and provides an accessible resource for clinicians in their routine practice.

Bookmark PCSK9 Forum to return for regular updates to this innovative expert-led educational slide resource programme.